Treatments on the Horizon: Breast Cancer Patients with Central Nervous System Metastases
Abstract
Purpose of review The goal of this paper is to provide a review on the current emerging management strategies as described in the literature pertaining to breast cancer and central nervous system metastases. As systemic oncology treatments evolve, so are new approaches to the management of central nervous system metastases from breast cancer.Recent findings In this review, we describe how novel treatment strategies have evolved from standard chemotherapy to more targeted approaches, innovative drug delivery methodologies, immunotherapeutics, and radiotherapeutic approaches. We describe innovative treatment strategies on the horizon for breast cancer and central nervous metastases. Future therapeutics may be better able to penetrate through the blood-brain-barrier bypassing limitations from standard therapies. These pioneering strategies will hopefully improve patients' quality of life as well as survival.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Atezolizumab improved progression-free survival in patients with metastatic breast cancer based on the Phase 3 IMpassion130 trial.
“These trial results demonstrated that Atezolizumab improved progression-free survival in patients with metastatic breast cancer.”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [58]
Cites
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115 · see citing works
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621 · see citing works
Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · see citing works
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J. J., Takeda, S., & Pommier, Y. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,217 · see citing works
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,183 · see citing works
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845 · see citing works
Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions
D’Amours, D., Desnoyers, S., D’Silva, I., & Poirier, G. G. (1999) · Biochemical Journal · doi:10.1042/bj3420249 · Cited by 1,819 · see citing works
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,540 · see citing works
Noninvasive MR Imaging–guided Focal Opening of the Blood-Brain Barrier in Rabbits
Hynynen, K., McDannold, N. J., Vykhodtseva, N. I., & Jolesz, F. A. (2001) · Radiology · doi:10.1148/radiol.2202001804 · Cited by 1,463 · see citing works
Gust, J., Hay, K. A., Hanafi, L.-A., Li, D., Myerson, D., Gonzalez-Cuyar, L. F., Yeung, C., Liles, W. C., Wurfel, M., Lopez, J. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0698 · Cited by 1,400 · see citing works
Role of poly(ADP-ribose) formation in DNA repair
Satoh, M. S., & Lindahl, T. L. (1992) · Nature · doi:10.1038/356356a0 · Cited by 1,181 · see citing works
Mfsd2a is critical for the formation and function of the blood-brain barrier
Ben-Zvi, A., Lacoste, B., Kur, E., Andreone, B. J., Mayshar, Y., Yan, H., & Gu, C. (2014) · Nature · doi:10.1038/nature13324 · Cited by 1,037 · see citing works
Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004 · see citing works
Lockman, P. R., Mittapalli, R. K., Taskar, K. S., Rudraraju, V., Gril, B., Bohn, K. A., Adkins, C. E., Roberts, A., Thorsheim, H. R., Gaasch, J. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1564 · Cited by 696 · see citing works
Hynynen, K., McDannold, N., Sheikov, N. A., Jolesz, F. A., & Vykhodtseva, N. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2004.06.046 · Cited by 679 · see citing works
Le Rhun, E., Weller, M., Brandsma, D., Van den Bent, M., de Azambuja, E., Henriksson, R., Boulanger, T., Peters, S., Watts, C., Wick, W., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx221 · Cited by 637 · see citing works
Mainprize, T. G., Lipsman, N., Huang, Y., Meng, Y., Bethune, A. J., Ironside, S., Heyn, C., Alkins, R. D., Trudeau, M., Sahgal, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-36340-0 · Cited by 625 · see citing works
André, F., Ciruelos, E. M., Juric, D., Loibl, S., Campone, M., Mayer, I. A., Rubovszky, G., Yamashita, T., Kaufman, B., Lu, Y.-S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.011 · Cited by 624 · see citing works
Sheikov, N. A., McDannold, N. J., Vykhodtseva, N. I., Jolesz, F. A., & Hynynen, K. (2004) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2004.04.010 · Cited by 619 · see citing works
Posey, A. D., Schwab, R. D., Boesteanu, A. C., Steentoft, C., Mandel, U., Engels, B., Stone, J. D., Madsen, T. D., Schreiber, K., Haines, K. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.014 · Cited by 594 · see citing works
Mechanisms of PARP inhibitor sensitivity and resistance
D’Andrea, A. D. (2018) · DNA repair · doi:10.1016/j.dnarep.2018.08.021 · Cited by 488 · see citing works
PI3K inhibitors are finally coming of age
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 487 · see citing works
Disrupting the blood–brain barrier by focused ultrasound induces sterile inflammation
Kovacs, Z. I., Kim, S., Jikaria, N., Qureshi, F., Milo, B., Lewis, B. K., Bresler, M., Burks, S. R., & Frank, J. A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614777114 · Cited by 458 · see citing works
Tchou, J. C., Zhao, Y., Levine, B. L., Zhang, P. J., Suhoski, M. M., Melenhorst, J. J., Kulikovskaya, I. M., Brennan, A. L., Liu, X., Lacey, S. F., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0189 · Cited by 453 · see citing works
Chen, Y., Wang, D., Peng, H., Chen, X., Han, X., Yu, J., Wang, W., Liang, L., Liu, Z., Zheng, Y., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0930-x · Cited by 440 · see citing works
Programming CAR-T cells to kill cancer
Labanieh, L., Majzner, R. G., & Mackall, C. L. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0235-9 · Cited by 439 · see citing works
Chemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check
Muldoon, L. L., Soussain, C., Jahnke, K., Johanson, C. E., Siegal, T., Smith, Q. R., Hall, W. A., Hynynen, K., Senter, P. D., Peereboom, D. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.9861 · Cited by 418 · see citing works
Pentsova, E. I., Shah, R. H., Tang, J., Boire, A. A., You, D., Briggs, S. R., Omuro, A. M. P., Lin, X., Fleisher, M., Grommes, C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6487 · Cited by 415 · see citing works
Stemmler, H., Schmitt, M., Willems, A., Bernhard, H., Harbeck, N., & Heinemann, V. (2006) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000236313.50833.ee · Cited by 411 · see citing works
DNA methyltransferases and their roles in tumorigenesis
Zhang, W., & Xu, J. (2017) · Biomarker Research · doi:10.1186/s40364-017-0081-z · Cited by 387 · see citing works
Ahmed, N. M., Salsman, V. S., Kew, Y., Shaffer, D. R., Powell, S. Z.-E., Zhang, Y. J., Grossman, R. G., Heslop, H. E., & Gottschalk, S. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1322 · Cited by 382 · see citing works
Priceman, S. J., Tilakawardane, D., Jeang, B., Aguilar, B., Murad, J. P., Park, A. K., Chang, W.-C., Ostberg, J. R., Neman, J., Jandial, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2041 · Cited by 326 · see citing works
Brain Metastases in Newly Diagnosed Breast Cancer
Martin, A. M., Cagney, D. N., Catalano, P. J., Warren, L. E., Bellon, J. R., Punglia, R. S., Claus, E. B., Lee, E. Q., Wen, P. Y., Haas-Kogan, D. A., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0001 · Cited by 302 · see citing works
Krop, I. E., Mayer, I. A., Ganju, V., Dickler, M. N., Johnston, S. R. D., Morales, S. M., Yardley, D. A., Melichar, B., Forero, A., Lee, S. C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00106-6 · Cited by 295 · see citing works
Arvanitis, C., Askoxylakis, V., Guo, Y., Datta, M., Kloepper, J., Ferraro, G. B., Bernabéu, M. O., Fukumura, D., McDannold, N. J., & Jain, R. K. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807105115 · Cited by 235 · see citing works
Leyland-Jones, B. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8481 · Cited by 233 · see citing works
Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells.
Moritz, D. R., Wels, W. S., Mattern, J., et al. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4318 · Cited by 210 · see citing works
Chen, G., Chakravarti, N., Aardalen, K., Lazar, A. J., Tetzlaff, M. T., Wubbenhorst, B. S., Kim, S.-B., Kopetz, S., Ledoux, A. A., Gopal, Y. N. V., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3003 · Cited by 204 · see citing works
Survival of breast cancer patients with meningeal carcinomatosis
Gauthier, H., Guilhaume, M. N., Bidard, F., Pierga, J., Girre, V., Cottu, P. H., Laurence, V., Livartowski, A., Mignot, L., & Dieras, V. C. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq232 · Cited by 184 · see citing works
Boire, A., Brandsma, D., Brastianos, P. K., Le Rhun, E., Ahluwalia, M., Junck, L., Glantz, M., Groves, M. D., Lee, E. Q., Lin, N., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz012 · Cited by 183 · see citing works
Martín, M., Chan, A., Dirix, L. Y., O’Shaughnessy, J., Hegg, R., Manikhas, A., Shtivelband, M. I., Криворотько, П. В., López, N. B., Campone, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw562 · Cited by 180 · see citing works
Narayan, P., Prowell, T. M., Gao, J. J., Fernandes, L. L., Li, E., Jiang, X., Qiu, J., Fan, J., Song, P., Yu, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3652 · Cited by 167 · see citing works
Abramson, J. S., Gordon, L. I., Palomba, M. L., Lunning, M. A., Arnason, J. E., Forero, A., Wang, M. L., Maloney, D. G., Sehgal, A. R., Andreadis, C. B., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.7505 · Cited by 166 · see citing works
Sperduto, P. W., Kased, N., Roberge, D., Chao, S. T., Shanley, R., Luo, X., Sneed, P. K., Suh, J. H., Weil, R. J., Jensen, A. W., et al. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1083-9 · Cited by 160 · see citing works
Ultrasound-mediated drug delivery to the brain: principles, progress and prospects
Dasgupta, A., Liu, M., Ojha, T., Storm, G., Kiessling, F. M., & Lammers, T. (2016) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2016.07.007 · Cited by 156 · see citing works
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
Brastianos, P. K., Lee, E. Q., Cohen, J. V., Tolaney, S. M., Lin, N., Wang, N., Chukwueke, U. N., White, M. D., Nayyar, N., Kim, A. E., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0918-0 · Cited by 151 · see citing works
Tiwary, S., Morales, J. E., Kwiatkowski, S. C., Lang, F. F., Rao, G., & McCarty, J. H. (2018) · Scientific Reports · doi:10.1038/s41598-018-26636-6 · Cited by 150 · see citing works
Alli, S. B., Figueiredo, C. A., Golbourn, B. J., Sabha, N., Wu, M., Bondoc, A., Luck, A. J., Coluccia, D., Maslink, C., Smith, C. A., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.005 · Cited by 148 · see citing works
Wise-Draper, T. M., Moorthy, G., Salkeni, M. A., Karim, N. A., Thomas, H. E., Mercer, C. A., Beg, M. S., O’Gara, S., Olowokure, O. O., Fathallah, H., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0482-9 · Cited by 119 · see citing works
Vuylsteke, P., Huizing, M. T., Petráková, K., Roylance, R. R., Laing, R. W., Chan, S. Y. T., Abell, F., Gendreau, S. B., Rooney, I. A., Apt, D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw320 · Cited by 116 · see citing works
Rhun, É. L., Wallet, J., Mailliez, A., Deley, M. L., Rodrigues, I., Boulanger, T., Lorgis, V., Barrière, J., Robin, Y. M., Weller, M., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz201 · Cited by 111 · see citing works
Todd, N., Angolano, C., Ferran, C. J., Devor, A., Borsook, D., & McDannold, N. J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.040 · Cited by 111 · see citing works
Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer
Dees, S., Ganesan, R., Singh, S., & Grewal, I. S. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0385 · Cited by 109 · see citing works
Clinical trial of proton craniospinal irradiation for leptomeningeal metastases
Yang, J. T., Wijetunga, N. A., Yamada, J., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa152 · Cited by 104 · see citing works
O’Reilly, M. A., Hough, O., & Hynynen, K. (2017) · Journal of Ultrasound in Medicine · doi:10.7863/ultra.16.02005 · Cited by 95 · see citing works
Atezolizumab for the treatment of breast cancer
Reddy, S. M., Carroll, E., & Nanda, R. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1732211 · Cited by 94 · see citing works
EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC
Liu, Y., Zhou, Y., Huang, K., et al. (2019) · Aging · doi:10.18632/aging.102510 · Cited by 93 · see citing works
Zhao, G., Huang, Q., Wang, F., Zhang, X., Hu, J., Tan, Y. C., Huang, N., Wang, Z., Wang, Z., & Cheng, Y. Z. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.035 · Cited by 90 · see citing works
Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?
Kabraji, S. K., Ni, J., Lin, N., Xie, S., Winer, E. P., & Zhao, J. J. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3351 · Cited by 90 · see citing works
Brain metastases free survival differs between breast cancer subtypes
Berghoff, A. S., Bagó-Horváth, Z., Vries, C. D., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.597 · Cited by 88 · see citing works
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
Madariaga, A., Bowering, V. L., Ahrari, S., Oza, A. M., & Lheureux, S. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-001288 · Cited by 86 · see citing works
Fazio, N., Buzzoni, R., Baudin, É., Antonuzzo, L., Hubner, R. A., Lahner, H., de Herder, W. W., Raderer, M., Teulé, À., Capdevila, J., et al. (2016) · PubMed · Cited by 85 · see citing works
Malani, R., Fleisher, M., Kumthekar, P., Lin, X., Omuro, A. M. P., Groves, M. D., Lin, N., Melisko, M., Lassman, A. B., Jeyapalan, S. A., et al. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03555-z · Cited by 84 · see citing works
Self-citationBuparlisib is a brain penetrable pan-PI3K inhibitor
de Gooijer, M. C., Zhang, P., Buil, L. C. M., Çitirikkaya, C. H., Thota, N., Beijnen, J. H., & van Tellingen, O. (2018) · Scientific Reports · doi:10.1038/s41598-018-29062-w · Cited by 78 · see citing works
PI3K: A master regulator of brain metastasis‐promoting macrophages/microglia
Blazquez, R., Wlochowitz, D., Wolff, A., Seitz, S., Wachter, A., Perera-Bel, J., Bleckmann, A., Beissbarth, T., Salinas, G., Riemenschneider, M., et al. (2018) · Glia · doi:10.1002/glia.23485 · Cited by 71 · see citing works
Rhun, É. L., Rudà, R., Devos, P., Hoang‐Xuan, K., Brandsma, D., Segura, P. P., Soffietti, R., & Weller, M. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2452-6 · Cited by 70 · see citing works
Smart CARs engineered for cancer immunotherapy
Priceman, S. J., Forman, S. J., & Brown, C. E. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000232 · Cited by 69 · see citing works
Ultrasound and the Blood-Brain Barrier
Patrick, J. T., Nolting, M. N., Goss, S. A., Dines, K. A., Clendenon, J. L., Rea, M. A., & Heimburger, R. F. (1990) · Advances in experimental medicine and biology · doi:10.1007/978-1-4684-5766-7_36 · Cited by 68 · see citing works
Poon, C., Pellow, C., & Hynynen, K. (2020) · Theranostics · doi:10.7150/thno.52710 · Cited by 68 · see citing works
Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors
DeRenzo, C. C., & Gottschalk, S. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00218 · Cited by 58 · see citing works
Poggio, F. B., Bruzzone, M., Ceppi, M., Conte, B., Martel, S., Maurer, C., Tagliamento, M., Viglietti, G., Mastro, L. D., de Azambuja, E., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000361 · Cited by 57 · see citing works
Zagouri, F., Zoumpourlis, P., Rhun, É. L., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102046 · Cited by 55 · see citing works
Ziegler, Y., Moresco, J. J., Yates, J. R., & Nardulli, A. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158296 · Cited by 51 · see citing works
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalvès, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L., Martín, M., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-gs6-07 · Cited by 50 · see citing works
Blood-brain barrier disruption induced by diagnostic ultrasound combined with microbubbles in mice
Zhao, B., Chen, Y., Liu, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23527 · Cited by 49 · see citing works
Niwińska, A., Pogoda, K., Michalski, W., Kunkiel, M., & Jagiełło-Gruszfeld, A. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2790-z · Cited by 49 · see citing works
Carausu, M., Carton, M., Darlix, A., Pasquier, D., Leheurteur, M., Debled, M., Mouret‐Reynier, M., Gonçalvès, A., Dalenc, F., Verret, B., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100150 · Cited by 48 · see citing works
Kyle, S., Thomas, H. D., Mitchell, J., & Curtin, N. J. (2008) · British Journal of Radiology · doi:10.1259/bjr/99111297 · Cited by 41 · see citing works
Robson, M. E., Im, S., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.18_suppl.lba4 · Cited by 40 · see citing works
Meng, Y., Suppiah, S., Surendrakumar, S., Bigioni, L., & Lipsman, N. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00338 · Cited by 39 · see citing works
Exman, P., Mallery, R. M., Lin, N., & Parsons, H. A. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0139-1 · Cited by 37 · see citing works
Thomssen, C., Lüftner, D., Untch, M., Haidinger, R., Würstlein, R., Harbeck, N., Augustin, D., Briest, S., Ettl, J., Fasching, P. A., et al. (2020) · Breast Care · doi:10.1159/000505957 · Cited by 37 · see citing works
Pascual, T., González‐Farré, B., Teixidó, C., Oleaga, L., Oses, G., Ganau, S., Chic, N., Riu-Viladoms, G., Adamo, B., Galván, P., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00012 · Cited by 24 · see citing works
Sambade, M. J., Swearingen, A. E. D. V., McClure, M. B., Deal, A. M., Santos, C., Sun, K., Wang, J., Mikule, K. W., & Anders, C. K. (2019) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdz005 · Cited by 22 · see citing works
PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer
Peddi, P. F., & Hurvitz, S. A. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1369-6 · Cited by 19 · see citing works
Tung, N., Im, S., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Li, W., Armstrong, A. C., Conte, P., Wu, W., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.1052 · Cited by 14 · see citing works
Nguyen, M., Robillard, L., Harding, T. C., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-3888 · Cited by 10 · see citing works
Anastasiadis, P., Winkles, J. A., Kim, A. J., & Woodworth, G. F. (2020) · Neuromethods · doi:10.1007/978-1-0716-1052-7_8 · Cited by 8 · see citing works
Ahmed, K. A., Kim, Y., DeJesus, M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.tps1099 · Cited by 7 · see citing works
Pistilli, B., Urruticoechea, A., Chan, S., et al. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)32887-8 · Cited by 6 · see citing works
Developing a Safe and Effective CAR T-Cell Immunotherapy for Breast Cancer: Progress and Pitfalls
Antoine, P., & Maher, J. F. (2020) · Breast Cancer Management · doi:10.2217/bmt-2020-0010 · Cited by 6 · see citing works
MR-Guided Focused Ultrasound for Brain Tumors
Meng, Y., Pople, C. B., Suppiah, S., et al. (2021) · CRC Press eBooks · doi:10.1201/9781003037095-22 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Immune Checkpoint Inhibitors in Cancer Therapy
Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353 · see citing works
- Authors
- Kaplan, A., Li, M. J., & Malani, R.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Malani, Rachna
- ORCID
- Malani, Rachna
- Venue
- Current Oncology Reports
- Published
- 2022-02-09
- Volume
- 24
- Issue
- 3
- Pages
- 343-350
- ISSN
- 1523-3790 (ISSN-L)
- 1534-6269
- OpenAlex
- W4211235634
- Cited by
- 4
- References
- 92
- Citations by year
- 2023: 2 · 2022: 1 · 2013: 1
- FWCI
- 0.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Oncology Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Brain Metastases and Treatment
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
- Keywords
- breast cancer, central nervous system metastasis, blood-brain barrier, targeted therapy, drug delivery, immunotherapy, radiotherapy, chemotherapy, new drugs
- MeSH terms
- Brain Neoplasms, Breast Neoplasms, Central Nervous System, Female, Humans, Quality of Life, Central Nervous System Neoplasms, Neoplasms, Second Primary
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
